Novartis (NYSE:NVS) Shares Gap Up – Time to Buy?

Novartis AG (NYSE:NVS) gapped up prior to trading on Tuesday . The stock had previously closed at $152.06, but opened at $162.15. Novartis shares last traded at $161.64, with a volume of 1,164,231 shares.

Key Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Remibrutinib cleared two Phase III multiple sclerosis trials. The oral drug significantly reduced annualized relapse rates versus teriflunomide (Aubagio) in relapsing multiple sclerosis and also showed favorable results on MRI lesion measures. Novartis said a combined analysis indicated a clinically meaningful delay in disability progression, strengthening the drug’s potential commercial profile and supporting plans for global regulatory submissions. Novartis oral multiple sclerosis drug meets main goal in late stage studies
• Positive Sentiment: The positive MS data are viewed as an important growth catalyst. Analysts and investors see remibrutinib as a potential future blockbuster in a large market, particularly because it outperformed an established treatment and reportedly showed no liver-safety signal. The results prompted a sharp prior-session rally and could improve confidence in Novartis’ longer-term product pipeline. Novartis’ Remibrutinib Delivers Positive Results in Late-Stage MS Studies
• Positive Sentiment: Novartis signed a potential $3.2 billion Hybrozyme agreement with Alteogen. The deal could expand access to Alteogen’s drug-delivery technology and support development or commercialization of future medicines, though the financial commitment and deal milestones may limit the near-term earnings benefit. Novartis Signs Up To $3.2B Hybrozyme Deal With Alteogen
• Neutral Sentiment: Novartis plans to relocate laboratory activities and shut down some Basel production operations, potentially affecting about 130 jobs. The restructuring may improve efficiency over time but creates near-term execution and employee-transition costs. Novartis could cut about 130 jobs in Basel site relocation
• Negative Sentiment: Novartis paused eight autoimmune and neurological cell-therapy trials after three patient deaths. The pauses raise safety, regulatory and development risks for the experimental rap-cel program and prompted a customer-related setback for Oxford BioMedica, though the issue is separate from remibrutinib. Novartis pauses autoimmune cell therapy studies after deaths

Wall Street Analyst Weigh In

Several research analysts recently weighed in on NVS shares. Citigroup restated a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Novartis presently has an average rating of “Hold” and a consensus target price of $141.20.

Novartis Stock Performance

The business’s 50-day simple moving average is $155.48 and its two-hundred day simple moving average is $153.74. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89. The firm has a market cap of $309.93 billion, a price-to-earnings ratio of 24.50, a P/E/G ratio of 3.14 and a beta of 0.45.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The firm had revenue of $14.95 billion for the quarter. As a group, sell-side analysts expect that Novartis AG will post 8.84 earnings per share for the current fiscal year.

Institutional Trading of Novartis

Institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley raised its position in Novartis by 14.9% during the fourth quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock worth $1,223,860,000 after acquiring an additional 1,148,033 shares during the period. Fisher Asset Management LLC grew its position in shares of Novartis by 3.1% in the fourth quarter. Fisher Asset Management LLC now owns 7,465,850 shares of the company’s stock valued at $1,029,317,000 after purchasing an additional 226,484 shares during the period. Bank of America Corp DE grew its position in shares of Novartis by 9.1% in the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock valued at $758,067,000 after purchasing an additional 413,778 shares during the period. Auto Owners Insurance Co increased its stake in shares of Novartis by 13,687.0% during the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock worth $638,103,000 after purchasing an additional 4,594,726 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Novartis by 10.3% during the 4th quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company’s stock worth $617,562,000 after purchasing an additional 419,988 shares during the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.